Publication: Impact of systemic inflammatory markers in patients with alk -positive non-small cell lung cancer treated with crizotinib
No Thumbnail Available
Date
2023-11-01
Authors
Çubukcu, Erdem
Authors
Ölmez, O. F.
Bilici, A.
Gürsoy, P.
Sakin, A.
Korkmaz, T.
Çil, I.
Çakar, B.
Menekse, S.
Demir, T.
Acıkgöz, O.
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Objectives: To evaluate the prognostic utility of inflammation-based prognostic scores in patients with ALK-positive metastatic or non-resectable non-small-cell lung cancer (NSCLC) treated with crizotinib.Patients and Methods: A total of 82 patients with ALK-positive metastatic or non-resectable NSCLC who received ALK TKI crizotinib were included. Pre-treatment modified Glasgow prognostic score (mGPS), prognostic nutritional index (PNI), and systemic immune-inflammation index (SII) were calculated. Multivariable logistic regression and Cox proportional hazards models were used to assess the impact of pretreatment mGPS, PNI, and SII on overall survival (OS), progression-free survival (PFS), and objective response rate (ORR).Results: The ORR was 77.2%, while 1-year OS and PFS rates were 95.0% and 93.5%, respectively. The univariate analysis revealed significantly higher 1-year PFS (89.4 vs. 64.4%, p=0.043) and OS (92.0 vs. 83.3%, p=0.01) rates in patients with low (<934.7) vs. high (>= 934.7) SII scores. Multivariate analysis revealed that PNI >= 0.09 was a significant determinant of poorer 1-year OS rates (hazard ratio [HR]: 2.46, 95% confidence interval [CI] 0.88-4.85, p=0.035). No significant difference was observed in survival rates according to gender, age, smoking status, prior lines of therapy, or mGPS scores, while higher mGPS scores (odds ratio [OR]: 0.1, 95%CI 0.16-1.04; p=0.009) and higher PNI scores (OR: 0.16, 95% CI 0.02-0.55; p=0.035) were associated with poorer ORR.Conclusion: Our findings indicate the prognostic significance of PNI and SII in terms of survival outcome and the impact of mGPS and PNI on treatment response in patients with ALK-positive NSCLC treated with crizotinib.
Description
Keywords
Prognostic nutritional index, Predicting prognosis, Lymphocyte ratio, Stage-i, Chemotherapy, Survival, Progression, Docetaxel, Outcomes, Scores, Nsclc, Alk-positive, Inflammation-based prognostic scores, Treatment response, Survival, Science & technology, Life sciences & biomedicine, Respiratory system